EAACI Congress 2024

31 May - 03 June 2024 Valencia, Spain

TPS76 - Biologicals 3

Sunday 02 Jun, 12:00 PM - 13:00 PM Valencia, Spain
Poster Zone Thematic Poster Session
A Phase 3 Open-Label Trial-In-Progress Evaluating Garadacimab For Prophylactic Treatment Of Pediatric Patients (Aged 2–11 Years) With Hereditary Angioedema
Characterization of anti-IgE molecules to inhibit IgE:receptor interactions and suppress IgE production in B-cells
Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tezepelumab in adult patients with severe chronic rhinosinusitis with nasal polyposis (WAYPOINT)
Effect of anti IL-5/IL-5Rα biological treatment on tissue eosinophil subpopulations in patients affected by Chronic Rhinosinusitis with Nasal Polyp
Eosinophilic systemic diseases: clinical characterization and efficacy of anti il5/il5-r therapy in a single center italian cohort
High-affinity omalizumab variants with optimized disruptive efficacy accelerate allergic effector cell desensitization
MY006: anti-allergen multispecific antibody for the treatment of peanut allergy
Mepolizumab for eosinophilic granulomatosis with polyangiitis (EGPA): a real-life experience in a single-center cohort
Mepolizumab simultaneously improves clinical outcomes in severe CRSwNP and asthma in the SYNAPSE study: Focus on global airway disease
Patients with severe eosinophilic asthma starting anti-IL5 treatment after 2018 have better preserved lung function compared to the patients who started treatment earlier
Real-life experience and the safety of Immunobiologicals in the treatment of immunoallergic diseases
Response to benralizumab in severe vernal keratoconjunctivitis after treatment failure with omalizumab
Treating idiopathic hypereosinophilic syndrome in the biologics era: an experience in a developing country